Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Fallopian Tube Neoplasms 5Ovarian Neoplasms 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Sarcoma, Alveolar Soft Part 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Leiomyosarcoma 1Intestinal Obstruction 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 39Paclitaxel 35Radiosurgery 30Gemcitabine 30Carboplatin 30Cisplatin 23Irinotecan 22Ipilimumab 22Cyclophosphamide 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14atezolizumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × cediranib × 1 year × Clear all
NCT00750841 2026-05-19

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

AstraZeneca

Phase 1 Active not recruiting
64 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡